COPD Insights for Primary Care: 5 New Studies

Slideshow

Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock

Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose

Sydney Jennings
April 21st 2025
Article

Your daily dose of the clinical news you may have missed.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden

Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden

Grace Halsey
March 27th 2025
Article

A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose

Sydney Jennings
March 20th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

Patient Care Editorial Staff
March 10th 2025
Article

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

© 2025 MJH Life Sciences

All rights reserved.